| Literature DB >> 35022007 |
Siyeon Suh1,2, Sol Lee1, Ho Gym1, Sanghyuk Yoon1, Seunghwan Park1, Jihi Cha1, Do-Hyung Kwon1, YunSu Yang1, Sun Ha Jee3.
Abstract
BACKGROUND: COVID-19, caused by SARS-CoV-2 has become the most threatening issue to all populations around the world. It is, directly and indirectly, affecting all of us and thus, is an emerging topic dealt in global health. To avoid the infection, various studies have been done and are still ongoing. COVID-19 cases are reported all over the globe, and among the millions of cases, genetic similarity may be seen. The genetical common features seen within confirmed cases may help outline the tendency of infection and degree severity of the disease. Here, we reviewed multiple papers on SNPs related to SARS-CoV-2 infection and analyzed their results.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35022007 PMCID: PMC8753023 DOI: 10.1186/s12879-022-07034-w
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Flow chart depicting literature search and selection process
Characteristics of the included studies
| First author (last name) | Publication year | Country | Journal | Database name | Number of subjects | Age (years) | Gene | SNP |
|---|---|---|---|---|---|---|---|---|
| Maiti et al. [ | 2020 | USA | Immunogenetics | 1000 genome project ( | N/A | N/A | IFIH1 | rs1990760 |
| Torre-Fuentes et al. [ | 2021 | Spain | Journal of Medical Virology | MS family cohort | 120 | N/A | ACE2, TMPRSS2 | rs75603675, rs61735792, rs61735794 |
| Gomez et al. [ | 2021 | Spain | Cytokine | Hospital Univ. Central Asturias, Spain | 311 | 65.23 | IFITM3 | rs12252 (C) |
| Zhang et al. [ | 2020 | China | The Journal of Infectious Diseases | Patients were recruited from Beijing Youan Hospital, Capital Medical University, Beijing, between January 2020 and February 2020 | 80 | 49.5 | IFITM3 | rs12252 (C) |
| Hussain et al. [ | 2020 | Pakistan | Journal of Medical Virology | Ensembl ( | N/A | N/A | ACE2 | rs7363582, rs143936283 |
| Gomez et al. [ | 2020 | Spain | Elsevier | Hospital Univ. Central Asturias, Spain | 740 | 67.44 | ACE, ACE2 | rs2285666 |
| Wang et al. [ | 2020 | China | Journal of General Virology | dbSNP ( | N/A | N/A | ACE2 | rs143936283 rs267606406 rs4646116 |
| Fujikura et al. [ | 2020 | Japan | Journal of clinical pathology | 1000G ( | 669 | N/A | ACE2, TMPRSS2 | N/A |
| Yamamoto et al. [ | 2020 | Japan | Elsevier | High-coverage sequenced data of the phase 3 panel of the international 1000 Genomes Project (1000Genomes) and the Korean Personal Genome Project (KPGP) | N/A | N/A | ACE, ACE2 | N/A |
| Sienko et al. [ | 2020 | Poland | Clinical Interventions in Aging | N/A | 6272 | N/A | ACE2, TMPRSS2, CD147 | N/A |
| Paniri et al. [ | 2021 | Iran | Gene Rep | NCBI, UniProtKB ( | 52,456 | N/A | ACE2 | rs149039346, rs147311723, rs714205, rs1514283, rs4646175, rs3746444, rs113808830, rs3751304 |
| Nguyen et al. [ | 2020 | Vietnam | PLoS One | A hospital in Vietnam | 44 | 15–74 | ACE2 | N/A |
| Senapati et al. [ | 2020 | India | J Ganet | GTEx ( | 26 | 60 or more | ACE2, TMPRSS2, CD26 | rs112657409, rs11910678, rs77675406, rs713400, rs13015258 |
| Novelli et al. [ | 2020 | Italy | Human Genomics | GnomAD | 131 | N/A | ACE2 | N/A |
| Vargas-Alarcón et al. [ | 2020 | Mexico | ELSEVIER | dbSNPs, Ensembl Genome Browser, and 1000 Genome Project databases | N/A | N/A | ACE2, TMPRSS2, TMPRSS11A, ELANE, CTSL | rs12329760 |
| Benetti et al. [ | 2020 | Italy | European Journal of Human Genetics | NIG-db, LOVD ( | 389 | N/A | ACE2 | rs775181355, rs762890235 |
| Strafella et al. [ | 2020 | Italy | MDPI | Ensembl, 1000 Genomes, GnomAD | 268 | 46 | ACE2 | rs35803318, rs41303171, rs774469453, rs773676270, rs2285666 |
| Shikov et al. [ | 2020 | Russia | Front Genet | gnomAD | 58 | N/A | ACE2 | rs146598386, rs73195521, rs755766792 |
| Srivastava et al. [ | 2020 | India | Front. Genet | 1000 genome project | N/A | N/A | ACE2 | rs2285666 |
| Yang et al. [ | 2020 | Taiwan | PNAS | GISAID, Illumina | 1932 | N/A | N/A | N/A |
| Kim et al. [ | 2020 | South Korea | MDPI | World Health Organization (WHO) COVID-19 dashboard | N/A | N/A | IFITM3, ACE2, TMPRSS2, IL6, LZTFL1 | rs6598045, rs12252, rs34481144, rs6598045ss |
Newcastle–Ottawa Scale to assess quality of studies involved in systematic review
| Selection | Outcome | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Representativeness of expressed cohort | Selection of non expressed cohort | Ascertainment of exposure | Outcome not present at the start of the study | Comparability | Assessment of outcomes | Length of follow-up | Adequacy of follow-up | Total score | |
| Maiti et al. [ | a | a | a | a | a | a | a | a | 8 |
| Torre-Fuentes et al. [ | b | a | a | a | a | a | a | a | 8 |
| Gomez et al. [ | b | a | a | a | a | a | a | a | 8 |
| Zhang et al. [ | b | a | a | a | a | a | a | a | 8 |
| Hussain et al. [ | b | a | a | a | a | a | a | a | 8 |
| Gomez et al. [ | b | a | a | a | a | a | a | a | 8 |
| Wang et al. [ | a | a | a | a | a | a | a | a | 8 |
| Fujikura et al. [ | a | a | a | a | a | a | a | a | 8 |
| Yamamoto et al. [ | b | a | a | a | a | a | a | a | 8 |
| Sienko et al. [ | a | a | a | a | a | a | a | a | 8 |
| Paniri et al. [ | a | a | a | a | a | a | a | a | 8 |
| Nguyen et al. [ | b | a | a | a | a | a | a | a | 8 |
| Senapati et al. [ | b | a | a | a | a | a | a | a | 8 |
| Novelli et al. [ | b | a | a | a | a | a | a | a | 8 |
| Vargas-Alarcón et al. [ | b | a | a | a | a | a | a | a | 8 |
| Benetti et al. [ | b | a | a | a | a | a | a | a | 8 |
| Strafella et al. [ | b | a | a | a | a | a | a | a | 8 |
| Shikov et al. [ | b | a | a | a | a | a | a | a | 8 |
| Srivastava et al. [ | b | a | a | a | a | a | a | a | 8 |
| Yang et al. [ | b | a | a | a | a | a | a | a | 8 |
| Kim et al. [ | a | a | a | a | a | a | a | a | 8 |
SNPs mentioned twice or more in the reviewed studies
| SNP | Gene | Mentioned paper |
|---|---|---|
| rs12252-C | IFITM3 | Gomez et al. [ |
| Zhang et al. [ | ||
| Kim et al. [ | ||
| rs143936283 | ACE2 | Hussain et al. [ |
| Wang et al. [ | ||
| rs2285666 | ACE2 | Strafella et al. [ |
| Srivastava et al. [ | ||
| rs41303171 | ACE2 | Torre-Fuentes et al. [ |
| Strafella et al. [ | ||
| rs35803318 | ACE2 | Torre-Fuentes et al. [ |
| Strafella et al. [ |
Genes mentioned twice or more in the reviewed studies and the according related SNPs mentioned
| Gene | Related SNPs | Role of the gene |
|---|---|---|
| ACE2 (angiotensin I converting enzyme 2) | rs75603675, rs2285666, rs879922, rs73635825, rs143936283, rs143936283 rs267606406 rs4646116, rs149039346, rs147311723, rs714205, rs1514283, rs4646175, rs3746444, rs113808830, rs3751304, rs112657409, rs11910678, rs77675406, rs713400, rs13015258, rs12329760, rs775181355, rs762890235, rs35803318, rs41303171, rs774469453, rs773676270, rs2285666, rs146598386, rs73195521, rs755766792, rs2285666, rs6598045 | SARS-CoV-2 spike protein entry receptor [ |
| IFITM3 (interferon-induced transmembrane protein 3) | rs12252-C, rs6598045 | Gene variants of IFITM3 are related to the infection of influenza and viruses. IFITM3 is significant in taking antiviral actions. It prevents cellular lipid bilayer from getting bisected by viruses [ |
| TMPRSS2 (transmembrane protease, serine 2) | rs61735794, rs61735792, rs75603675, rs112657409, rs11910678, rs77675406, rs713400, rs13015258, rs12329760 | Cleavage of TMPRSS2 activates influenza virus hemagglutinin and the human metapneumovirus F protein [ |